Isthmus Partners LLC Has $3.31 Million Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Isthmus Partners LLC lowered its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 20.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 132,047 shares of the medical equipment provider’s stock after selling 33,200 shares during the quarter. Isthmus Partners LLC owned 0.29% of BioLife Solutions worth $3,306,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BLFS. State Board of Administration of Florida Retirement System acquired a new position in BioLife Solutions during the 1st quarter worth approximately $229,000. Vanguard Group Inc. raised its stake in shares of BioLife Solutions by 11.5% during the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after purchasing an additional 296,727 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of BioLife Solutions by 11.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 33,158 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 3,464 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 1,374 shares in the last quarter. Finally, Bard Financial Services Inc. raised its stake in shares of BioLife Solutions by 42.4% during the 2nd quarter. Bard Financial Services Inc. now owns 190,300 shares of the medical equipment provider’s stock worth $4,078,000 after purchasing an additional 56,665 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BLFS shares. Northland Securities upped their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. HC Wainwright dropped their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $27.50.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,396,428.48. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,644 shares of company stock worth $1,527,503. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Up 0.4 %

BLFS opened at $27.16 on Friday. BioLife Solutions, Inc. has a 1-year low of $11.91 and a 1-year high of $28.88. The stock’s fifty day simple moving average is $24.16 and its 200 day simple moving average is $23.16. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.26 billion, a PE ratio of -25.62 and a beta of 1.88.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.